Selecting Cytotoxic Partner For Pembrolizumab in PD-L1+ TNBC | Targeted Oncology

Although HER2 and hormone therapy approaches are ineffective for patients with triple-negative breast cancer (TNBC), using immunotherapy in those with positive PD-L1 expression has been shown to improve on standard chemotherapy. In a virtual…